Loading…
Reported covered position: Intern, Sen. Portman (2017)
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Medicaid VBPs for Patients Act
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Medicaid VBPs for Patients Act
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
GENETIX BIOTHERAPEUTICS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · first_quarter · Q1
Issues and legislation related to access to gene therapies and treatment of rare diseases.
Issues and legislation related to access to gene therapies and treatment of rare diseases.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
Medicaid VBPs for Patients Act
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Medicaid VBPs for Patients Act
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Legislation related to antikickback exclusions for travel and lodging arrangements between manufacturers of drugs and patients
Medicaid VBPs for Patients Act
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Medicaid VBPs for Patients Act
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Medicaid VBPs for Patients Act
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Legislation related to antikickback exclusions for travel and lodging arrangements between manufacturers of drugs and patients
Medicaid VBPs for Patients Act
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Creating Hope Reauthorization Act of 2024
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Legislation related to antikickback exclusions for travel and lodging arrangements between manufacturers of drugs and patients
Creating Hope Reauthorization Act of 2024
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Creating Hope Reauthorization Act of 2024
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Creating Hope Reauthorization Act of 2024
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Creating Hope Reauthorization Act of 2024
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Legislation related to antikickback exclusions for travel and lodging arrangements between manufacturers of drugs and patients
Creating Hope Reauthorization Act of 2024
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Patient Access Act of 2024
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Patient Access Act of 2024
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Patient Access Act of 2024
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Patient Access Act of 2024
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Creating Hope Reauthorization Act of 2024
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Creating Hope Reauthorization Act of 2024
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Creating Hope Reauthorization Act of 2024
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Legislation related to antikickback exclusions for travel and lodging arrangements between manufacturers of drugs and patients
Creating Hope Reauthorization Act of 2024
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Legislation related to antikickback exclusions for travel and lodging arrangements between manufacturers of drugs and patients
Creating Hope Reauthorization Act of 2024
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Creating Hope Reauthorization Act of 2024
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Medicaid VBPs for Patients Act
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Medicaid VBPs for Patients Act
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Medicaid VBPs for Patients Act
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Medicaid VBPs for Patients Act
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Medicaid VBPs for Patients Act
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Medicaid VBPs for Patients Act
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Medicaid VBPs for Patients Act
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Medicaid VBPs for Patients Act
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
2024 · fourth_quarter · Q4
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
PHARMAESSENTIA USA CORPORATION via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · fourth_quarter · Q4
Issues related to implementation of the Inflation Reduction Act (IRA, P.L. 117-169).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PHARMAESSENTIA USA CORPORATION via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · third_quarter · Q3
Issues related to implementation of the Inflation Reduction Act (IRA, P.L. 117-169).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
GENETIX BIOTHERAPEUTICS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · third_quarter · Q3
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
PHARMAESSENTIA USA CORPORATION via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · third_quarter · RA
Issues related to implementation of the Inflation Reduction Act (IRA, P. L. 117-169).
PHARMAESSENTIA USA CORPORATION via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · third_quarter · RR
Issues related to implementation of the Inflation Reduction Act (IRA, P. L. 117-169).
GENETIX BIOTHERAPEUTICS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · second_quarter · Q2
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Legislation related to antikickback exclusions for travel and lodging arrangements between manufacturers of drugs and patients
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Legislation related to antikickback exclusions for travel and lodging arrangements between manufacturers of drugs and patients
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
GENETIX BIOTHERAPEUTICS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · first_quarter · Q1
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
GENETIX BIOTHERAPEUTICS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · fourth_quarter · Q4
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GENETIX BIOTHERAPEUTICS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · third_quarter · Q3
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GENETIX BIOTHERAPEUTICS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · second_quarter · Q2
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENETIX BIOTHERAPEUTICS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · second_quarter · RR
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).